SG10201809701TA - Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent - Google Patents

Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Info

Publication number
SG10201809701TA
SG10201809701TA SG10201809701TA SG10201809701TA SG10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA SG 10201809701T A SG10201809701T A SG 10201809701TA
Authority
SG
Singapore
Prior art keywords
peptide
chemotherapeutic agent
mutant ras
vaccine
cancer
Prior art date
Application number
SG10201809701TA
Other languages
English (en)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809701T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of SG10201809701TA publication Critical patent/SG10201809701TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201809701TA 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent SG10201809701TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06

Publications (1)

Publication Number Publication Date
SG10201809701TA true SG10201809701TA (en) 2018-12-28

Family

ID=50679896

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608712PA SG11201608712PA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
SG10201809701TA SG10201809701TA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608712PA SG11201608712PA (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Country Status (16)

Country Link
US (1) US9757439B2 (ja)
EP (1) EP3140320B1 (ja)
JP (2) JP2017514847A (ja)
KR (1) KR20170002563A (ja)
CN (1) CN106414493A (ja)
AU (1) AU2015257774B2 (ja)
BR (1) BR112016025764A2 (ja)
CA (1) CA2947963A1 (ja)
CL (1) CL2016002794A1 (ja)
DK (1) DK3140320T3 (ja)
ES (1) ES2716923T3 (ja)
IL (1) IL248671B (ja)
MX (1) MX2016014414A (ja)
RU (1) RU2700929C2 (ja)
SG (2) SG11201608712PA (ja)
WO (1) WO2015169804A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3363457A1 (en) 2013-12-09 2018-08-22 Targovax Asa A peptide mixture
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (zh) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
WO2020252039A1 (en) * 2019-06-12 2020-12-17 Biontech Us Inc. Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
CN116261465A (zh) * 2020-07-29 2023-06-13 Sqz生物技术公司 使用有核细胞刺激对突变体ras的免疫应答的方法
KR20230058388A (ko) * 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 무핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CN104147597A (zh) 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3363457A1 (en) 2013-12-09 2018-08-22 Targovax Asa A peptide mixture

Also Published As

Publication number Publication date
MX2016014414A (es) 2017-02-23
RU2016147527A3 (ja) 2019-01-21
RU2016147527A (ru) 2018-06-08
ES2716923T3 (es) 2019-06-18
DK3140320T3 (en) 2019-04-15
CA2947963A1 (en) 2015-11-12
RU2700929C2 (ru) 2019-09-24
AU2015257774B2 (en) 2018-12-20
IL248671A0 (en) 2017-01-31
US9757439B2 (en) 2017-09-12
SG11201608712PA (en) 2016-11-29
CL2016002794A1 (es) 2017-06-09
CN106414493A (zh) 2017-02-15
JP7304629B2 (ja) 2023-07-07
EP3140320A1 (en) 2017-03-15
AU2015257774A1 (en) 2016-12-22
JP2017514847A (ja) 2017-06-08
US20170065694A1 (en) 2017-03-09
KR20170002563A (ko) 2017-01-06
BR112016025764A2 (pt) 2018-01-16
WO2015169804A1 (en) 2015-11-12
JP2020100650A (ja) 2020-07-02
EP3140320B1 (en) 2018-12-26
IL248671B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
IL304717A (en) Antibody conjugates against cmet with drug and methods of using them
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
MD4733C1 (ro) Anticorpi anti-TIGIT
MY187540A (en) Compounds active towards bromodomains
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2015016627A (es) Vacuna para la malaria.
MY191539A (en) Streptococcal vaccine
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3348643A4 (en) MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
TWD185782S (zh) 電腦之部分
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
PH12017501979A1 (en) Pharmaceutical compound
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
AR097179A1 (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y flupirtina
PL3630188T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
TWD174083S (zh) 電連接器之部分
GEP20207081B (en) Process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions